Johnson & Johnson Board of Directors

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Mr. Robert J. Decker Jr.

Mr. Robert J. Decker Jr.

Controller & Chief Accounting Officer

Mr. James Swanson

Mr. James Swanson

Executive VP & Chief Information Officer

Ms. Jessica Moore

Ms. Jessica Moore

Vice President of Investor Relations

Ms. Elizabeth Forminard J.D.

Ms. Elizabeth Forminard J.D.

Executive VP & Chief Legal Officer

Ms. Jennifer L. Taubert

Ms. Jennifer L. Taubert

Executive VP & Worldwide Chairman of Innovative Medicine

Dr. John C. Reed M.D., Ph.D.

Dr. John C. Reed M.D., Ph.D.

Executive Vice President of Innovative Medicine, R&D

Mr. Dirk Brinckman

Mr. Dirk Brinckman

Chief Compliance Officer

Dr. Guy J. Lebeau M.D.

Dr. Guy J. Lebeau M.D.

Group Chairman of MD&D Business - EMEA

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.